Pioneering biotech disrupts beauty industry with natural alternative to filler and Botox
Uvence, a company pioneered by leading cosmetic surgeon Dr. Olivier Amar and Profit500 business leader Reece Tomlinson, is disrupting the non-surgical cosmetic treatment market with a quality-controlled and 100% natural skin rejuvenation treatment.
The procedure is the only one of its kind fully regulated by the Human Tissue Authority (HTA), and provides a revolutionary on-demand cosmetic treatment tool to cosmetic doctors and clinics across the UK.
The company, which launched its treatment in London last week, is backed by a suite of private investors hailing from the UK, France, Monaco, Greece, the Middle East and Canada. Following their early success and growing popularity, Uvence is currently preparing for a raise in September 2020.
Recent reports from Laing Buisson has suggested that the non-surgical cosmetic treatment market is currently worth well in excess of over £2bn in the UK alone, with the global beauty market amounting to over £400bn. As the popularity of minimally invasive cosmetic treatments, or “tweakments”, grows to become an extension of a regular beauty regime for many, the market has experienced rapid growth in recent years, with botox and filler treatments among some of the most sought after procedures. Yet despite such rapid growth, industry commentators have identified the lack of standardisation and regulation as a key sticking point, which may represent a significant hurdle in the near future and prevent cosmetic treatment companies from scaling.
The Uvence treatment
Uvence creates its personalised products from a patient’s own fat cells, which are extracted by an initial micro or mini liposuction. Upon extraction, the fat cells are purified to create Uvence’s patented “Super Enriched Tissue”, before being reinjected to transform the look, feel and complexion of problem areas of the skin; including the face, neck, décolletage and hands.
Uvence will also cryogenically preserve a patient’s purified tissue for up to 5 years, thereby providing Uvence’s patients with a long-term, natural solution to maintain a rejuvenated, youthful aesthetic. The standardisation of the procedure gives comfort that each treatment will be as reliable as the last, and empowers the patient to take full control of their treatment, deciding when and where their injections will be administered.
The future of beauty is personal
In addition to this never-before-seen standardised approach to cosmetic treatments, Uvence are also offering a uniquely personal service to customers. In recent years, the beauty industry has begun to trend toward diversity in their products. Cosmetics, for example, have evolved from a one-sized fits all approach with very limited options, to the current day in which beauty products are developed for people of all backgrounds, skin tones and skin types.
As this trend continues to develop, the future of the beauty and cosmetic treatment industry will become more and more personal. Uvence are peerless in their provision of treatments which are completely unique to each individual, by providing a treatment which uses a patient’s own purified tissue to regenerate their skin.
Dr. Olivier Amar – leading cosmetic surgeon and Chief Medical Officer of Uvence
Dr. Olivier Amar is one of Europe’s leading aesthetic consultants, with over 15 years of experience in cosmetic, plastic and reconstructive surgery. As one of the leading Olivier has become the pioneering surgeon in fat-transfer in the UK, and has been instrumental in the development of the revolutionary Uvence treatment.
“This really is the future of cosmetic skin treatments, it is hugely exciting to see the next step in standardisation and quality for this kind of treatment. The Uvence offering allows access to regenerative and personalised treatments and is the biggest advance in the field for nearly 15 years. In terms of accessibility and convenience this has never been seen before, the cryopreservation capability allows plastic and cosmetic surgeons alike to provide this treatment on a consistent basis to their patients without the need for further liposuction or tissue extraction.”